OvaWatchSM is our newest ovarian cancer risk assessment launching in 2022. With its superior negative predictive value, OvaWatch is a non‑invasive test intended for use in assessing the risk of ovarian cancer for women with adnexal masses that have been considered indeterminate or benign in initial clinical assessment.

The OvaWatch blood test combines the results of:

• Seven tumor biomarkers
• Age
• Menopausal status

Provide a single risk assessment score delivering a Negative Predictive Value of over 99%1

Giving you confidence in a negative result for both premenopausal and postmenopausal patients

OvaWatch Biomarkers

The OvaWatch report includes:

Utilize OvaWatch in your practice to confidently develop your 
management plans.

A single blood draw —– which can be performed in a healthcare provider’s offices using our proprietary testing kit or at a number of national and regional laboratories — is all that is needed.

  1. Analytical Validation of a Deep Neural Network Algorithm for the Detection of Ovarian Cancer. Reilly G, Bullock R, Greenwood J, Ure DR, Stewart E, Davidoff P, DeGrazia J, Fritsche H, Dunton CJ, Bhardwaj N, and Northrop LE. JCO Clinical Cancer Informatics 6:e2100192 2022